Difference in the short-term outcomes of laparoscopic gastrectomy for gastric carcinoma between the east and west: a retrospective study from the IMIGASTRIC trial

Conclusions: The selections and short-term surgical outcomes of LG for GC were widely different between East and West. To obtain more objective and accurate results, these differences should be considered in future international prospective studies.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research

Related Links:

Conclusion: This study demonstrates the unequal manifestation of EOGC within the two ethnic groups of Han and Yi. However, familial clustering was infrequent. Further investigations are necessary to discover relevant risk factors apart from hereditary predisposition. PMID: 32231466 [PubMed - in process]
Source: The Scientific World Journal - Category: Science Tags: ScientificWorldJournal Source Type: research
ConclusionsIntracorporeal anastomosis using linear staplers reduced anastomotic bleeding and stenosis compared to extracorporeal anastomosis after LTG. Future research will be required to determine the ideal method for intracorporeal anastomosis in LTG.
Source: Surgical Endoscopy - Category: Surgery Source Type: research
In conclusion, TEADi is a valuable research tool for studying YAP1/TAZ and the Hippo pathway in cancer and other pathologies, with improved advantages that include rapid and simple inhibition of TEAD transcription and specific blockage of nuclear events mediated by both YAP1 and TAZ without affecting structural or cytoplasmic functions of these proteins.The NCILaboratory of Cellular and Molecular Biologyis seeking statements of capability or interest from parties interested in licensing this novel inhibitor of the Hippo signaling pathway.IC: NCINIH Ref. No.: E-108-2019Advantages: Rapid and simple inhibition ...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
ConclusionsWe concluded that CAF are a major source of GAS6 and that GAS6 promotes an aggressiveness through AXL activation in GC. We suggested that an AXL inhibitor may be a novel agent for GC treatment.
Source: Gastric Cancer - Category: Gastroenterology Source Type: research
Conditions:   Clinical Stage IV Gastric Cancer AJCC v8;   Clinical Stage IVA Gastric Cancer AJCC v8;   Clinical Stage IVB Gastric Cancer AJCC v8;   Malignant Uterine Neoplasm;   Metastatic Colorectal Carcinoma;   Metastatic Gastric Carcinoma;   Metastatic Malignant Neoplasm in  the Peritoneum;   Metastatic Ovarian Carcinoma;   Pathologic Stage IV Gastric Cancer AJCC v8;   Peritoneal Carc...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSIONS EphA1 can promote the occurrence and development of GC by its selective high expression in cancer tissues and its relationship with malignant clinical features and prognosis of GC patients. The underlying potential mechanism appears to involve enhancement of the tumor microenvironment, which via drives the expression of tumor microenvironment hallmark proteins IL-6 and VEGF. PMID: 32218416 [PubMed - as supplied by publisher]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
AbstractNearly 50% of primary lung carcinoma patients present with distant metastasis at their first visit. However, gastrointestinal tract (GIT) metastasis is an infrequent impediment. Herein, we report a case of progressive dysphagia and epigastralgia as an initial manifestation of recurrence as gastric metastasis of primary lung squamous cell carcinoma (SCC) after curative surgery. A 64 ‐year‐old man was diagnosed with primary lung SCC of the right lower lobe, and underwent thoracoscopic lower lobectomy. One year after lobectomy, computed tomography (CT) scan showed a gastric fundal mass located in the gastric cardi...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: CASE REPORT Source Type: research
ConclusionsHere, we discuss the role of ErbB4 in normal physiology and in breast, lung, colorectal, gastric, pancreatic, prostate, bladder, and brain cancers, as well as in hepatocellular carcinoma, cholangiocarcinoma, and melanoma. Understanding the role of ErbB4 in cancer is not only important for the treatment of tumors, but also for the treatment of other disorders in which ErbB4 plays a major role, e.g. cardiovascular disease.
Source: Cellular Oncology - Category: Cancer & Oncology Source Type: research
Abstract Goodyschle A (1), a new butenolide, was isolated from the whole grass of Goodyera schlechtendaliana, an orchidaceous edible medicinal plant. The structure of the new compound was elucidated by 1 D and 2 D NMR experiments in addition to HRESIMS analyses. Compound 1 was evaluated for its bioactivities including cytotoxic activity against human gastric cancer (SGC-7901) and human hepatocellular carcinoma (HepG2) cell lines, inhibitory activity on acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), and DPPH radical scavenging activity. As a result, compound 1 showed potent BChE inhibit...
Source: Natural Product Research - Category: Biochemistry Authors: Tags: Nat Prod Res Source Type: research
ConclusionsOur findings imply that miR-BART5-5p directly targets PIAS3 and augments PD-L1 through miR-BART5/PIAS3/pSTAT3/PD-L1 axis control. This contributes to antiapoptosis, tumor cell proliferation, invasion and migration, as well as immune escape, furthering gastric carcinoma progression and worsening the clinical outcome, especially in the PD-L1(+) group of patients with EBV-associated gastric carcinomas. miR-BART5-5p may, therefore, be amenable to PD-1/PD-L1 immune checkpoint inhibitor therapy.
Source: Gastric Cancer - Category: Gastroenterology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Clinical Trials | Gastrectomy | Gastric (Stomach) Cancer | Gastroenterology | Laparoscopy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Study